MNKD - マンカインド (MannKind Corporation) マンカインド

 MNKDのチャート


 MNKDの企業情報

symbol MNKD
会社名 MannKind Corp (マンカインド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マンカインド(MannKind Corporation)は開発段階の生物薬剤学企業であり、糖尿病と癌など疾患用の治療薬の発見・開発・商業化に集中する。同社の製品候補AFREZZA(ヒトインスリン)吸入パウダーは、血糖コントロールのための1型や2型糖尿病を患う成人向けの治療用の後期臨床研究段階にあるインスリン。AFREZZA吸入パウダーは、酸性・塩基性度(pH) 感知の有機分子クラスに集中する。AFREZZAはテクノスフィア処方設計技術を利用する。平成23年12月31日現在、同社の製品より収入はない。平成23年12月31日現在、AFREZZA臨床プログラムは、61の異なるAFREZZA研究及び5600以上の成人患者を含まれている。   マンカインドは米国のバイオ医薬品メ―カ―。主に糖尿病疾患の治療薬の発見・開発・製品化に従事。製品候補のAFREZZA(ヒトインスリン)吸入粉末は、I型またはII型糖尿病成人における血糖コントロ―ルを改善する可能性がある。AFREZZAはテクノスフィア製剤技術を利用している。本社はカリフォルニア州。   MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
本社所在地 25134 Rye Canyon Loop Suite 300 Valencia CA 91355 USA
代表者氏名 Kent Kresa ケント・クレッサ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 818-661-5000
設立年月日 33270
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 192人
url www.mannkindcorp.com
nasdaq_url https://www.nasdaq.com/symbol/mnkd
adr_tso
EBITDA EBITDA(百万ドル) -98.39600
終値(lastsale) 1.71
時価総額(marketcap) 271441752.57
時価総額 時価総額(百万ドル) 304.44680
売上高 売上高(百万ドル) 13.93100
企業価値(EV) 企業価値(EV)(百万ドル) 407.62780
当期純利益 当期純利益(百万ドル) -118.73000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MannKind Corporation revenues increased 42% to $7.4M. Net loss increased 3% to $53.1M. Revenues reflect Net revenue - commercial product sales increase from $2.7M to $7.2M Net revenue - collaboration increase of 19% to $150K. Higher net loss reflects General and Administrative increase of 25% to $42.3M (expense) Interest Exp-Net of Capitalized Interest increase of 51% to $2.2M (expense).

 MNKDのテクニカル分析


 MNKDのニュース

   The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations  2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   MannKind Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/11/04 18:59:00 Stock Market Daily
MannKind announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Recent Investment Analysts’ Ratings Changes for MannKind (MNKD)  2020/10/23 11:30:56 Dakota Financial News
A number of firms have modified their ratings and price targets on shares of MannKind (NASDAQ: MNKD) recently: 10/20/2020 – MannKind was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 10/7/2020 – MannKind was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According […]
   MannKind (NASDAQ:MNKD) Upgraded at BidaskClub  2020/10/23 06:44:58 Stock Observer
BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports. A number of other research firms also recently commented on MNKD. Zacks Investment Research downgraded MannKind from a buy rating to a hold rating in a research note on Wednesday, October […]
   MannKind (NASDAQ:MNKD) Rating Increased to Hold at BidaskClub  2020/10/22 03:42:46 Dispatch Tribunal
MannKind (NASDAQ:MNKD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports. MNKD has been the subject of several other reports. Zacks Investment Research downgraded MannKind from a “buy” rating to a “hold” rating in a research note on Wednesday, […]
   The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations  2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   MannKind Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2020/11/04 18:59:00 Stock Market Daily
MannKind announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Recent Investment Analysts’ Ratings Changes for MannKind (MNKD)  2020/10/23 11:30:56 Dakota Financial News
A number of firms have modified their ratings and price targets on shares of MannKind (NASDAQ: MNKD) recently: 10/20/2020 – MannKind was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 10/7/2020 – MannKind was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According […]
   MannKind (NASDAQ:MNKD) Upgraded at BidaskClub  2020/10/23 06:44:58 Stock Observer
BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports. A number of other research firms also recently commented on MNKD. Zacks Investment Research downgraded MannKind from a buy rating to a hold rating in a research note on Wednesday, October […]
   MannKind (NASDAQ:MNKD) Rating Increased to Hold at BidaskClub  2020/10/22 03:42:46 Dispatch Tribunal
MannKind (NASDAQ:MNKD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports. MNKD has been the subject of several other reports. Zacks Investment Research downgraded MannKind from a “buy” rating to a “hold” rating in a research note on Wednesday, […]
   Recent Investment Analysts’ Ratings Changes for MannKind (MNKD)  2020/10/23 11:30:56 Dakota Financial News
A number of firms have modified their ratings and price targets on shares of MannKind (NASDAQ: MNKD) recently: 10/20/2020 – MannKind was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 10/7/2020 – MannKind was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According […]
   MannKind (NASDAQ:MNKD) Upgraded at BidaskClub  2020/10/23 06:44:58 Stock Observer
BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports. A number of other research firms also recently commented on MNKD. Zacks Investment Research downgraded MannKind from a buy rating to a hold rating in a research note on Wednesday, October […]
   MannKind (NASDAQ:MNKD) Rating Increased to Hold at BidaskClub  2020/10/22 03:42:46 Dispatch Tribunal
MannKind (NASDAQ:MNKD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports. MNKD has been the subject of several other reports. Zacks Investment Research downgraded MannKind from a “buy” rating to a “hold” rating in a research note on Wednesday, […]
   MannKind Co. (NASDAQ:MNKD) Expected to Announce Quarterly Sales of $15.74 Million  2020/10/21 15:24:42 The Olympia Report
Analysts expect MannKind Co. (NASDAQ:MNKD) to report sales of $15.74 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for MannKind’s earnings, with estimates ranging from $15.50 million to $16.00 million. MannKind reported sales of $14.60 million in the same quarter last year, which indicates a positive year over year […]
   BidaskClub Upgrades MannKind (NASDAQ:MNKD) to “Hold”  2020/10/20 02:24:45 Daily Political
BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a research note released on Tuesday morning, BidAskClub reports. A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered MannKind from a buy rating to a hold rating in a research report […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マンカインド MNKD MannKind Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)